ArticleScientific reports2019
Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 28 citations in OpenAlex.
- Emerging precision medicine in multiple myeloma: clinical and preclinical landscape of T cell, natural killer cell, and macrophages engaging multi-specific antibodies.Frontiers in immunology · 2026Review
- A universal chimeric antigen receptor (CAR)-fragment antibody binder (FAB) split system for cancer immunotherapy.Science advances · 2025Article
- Bystander CARJournal for immunotherapy of cancer · 2025Article
- Adoptive cell therapy for cancer: combination strategies and biomarkers.Frontiers in immunology · 2025Review
- Development of a highly sensitive platform for protein-protein interaction detection and regulation of T cell function.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Fusion of NY-ESO-1 epitope with heat shock protein 70 enhances its induced immune responses and antitumor activity against gliomaTranslational cancer research · 2024Article
- Bi-specific T-cell engagers (BiTEs) in prostate cancer and strategies to enhance development: hope for a BiTE-r future.Frontiers in pharmacology · 2024Review
- Exploring TCR-like CAR-Engineered Lymphocyte Cytotoxicity against MAGE-A4.International journal of molecular sciences · 2023Article
- Cancer/testis antigens: promising immunotherapy targets for digestive tract cancers.Frontiers in immunology · 2023Review
- A novel TanCAR targeting IL13Rα2 and EphA2 for enhanced glioblastoma therapy.Molecular therapy oncolytics · 2022Article
- Combination Therapy of Hepatocellular Carcinoma by GPC3-Targeted Bispecific Antibody and Irinotecan is Potent in Suppressing Tumor Growth in Mice.Molecular cancer therapeutics · 2022Article
- Single-cell imaging of T cell immunotherapy responses in vivo.The Journal of experimental medicine · 2021Article
- Converting an Anti-Mouse CD4 Monoclonal Antibody into an scFv Positron Emission Tomography Imaging Agent for Longitudinal Monitoring of CD4Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Bispecific Antibodies in Multiple Myeloma: Present and Future.Blood cancer discovery · 2021Review
- Article
- A single-chain antibody generation system yielding CAR-T cells with superior antitumor function.Communications biology · 2021Article
- Review
- Bispecific T cell engagers and their synergistic tumor immunotherapy with oncolytic viruses.American journal of cancer research · 2021Review
- Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions.Frontiers in immunology · 2020Review
- Empirical and Rational Design of T Cell Receptor-Based Immunotherapies.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of chimeric antigen receptor (CAR) and bispecific T-cell engager (BiTE) has led to the successful application of cancer immunotherapy. The potential reactivity mediated by CAR- and BiTE-redirected T cells needs to be assessed to facilitate the application of these treatment options to a broader range of patients. Here, we have generated CAR and BiTE possessing the same single chain fragment variable (scFv) specific for the HLA-A2/NY-ESO-1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.